Why did Compass Pathways (NASDAQ:CMPS) publish 26-week data for its COMP360 trial?

Compass Pathways (NASDAQ:CMPS) published the 26-week clinical results to demonstrate the long-term durability and reproducibility of its synthetic psilocybin treatment. The company aims to establish a new mental health standard of care by replacing standard daily antidepressants with a therapeutic option requiring only a few treatments per year.

What are the primary efficacy and statistical numbers from the Compass Pathways (NASDAQ:CMPS) study?

The Compass Pathways (NASDAQ:CMPS) study showed that 39% of patients in the 25 mg group achieved a clinically meaningful reduction of 25% or more on depression scales at week 6 and maintained that improvement through week 26. Additionally, nearly 30% of those clinical responders entered complete remission following a scheduled retreatment dose.

How is the patient headcount managed in the Compass Pathways (NASDAQ:CMPS) depression program?

The Phase 3 COMP006 clinical trial evaluated a large medical registry containing nearly 600 active patients diagnosed with severe treatment-resistant depression. This clinical population exhibited a high degree of baseline chronicity, having experienced an average of more than six lifetime depressive episodes prior to trial enrollment.

What is the projected regulatory timeline for the Compass Pathways (NASDAQ:CMPS) drug application?

The company is currently processing an active rolling New Drug Application submission with federal reviewers and expects a finalized submission in the fourth quarter of 2026. If the application secures FDA approval and standard federal DEA rescheduling, a commercial launch is anticipated during the first half of 2027.

What commercial market impact does Compass Pathways (NASDAQ:CMPS) anticipate from this platform?

Compass Pathways (NASDAQ:CMPS) expects COMP360 to capture a substantial share of the global neuropsychiatry market by serving millions of patients failed by traditional antidepressants. The company stated that proving consistent, durable clinical outcomes across two massive Phase 3 studies significantly reduces commercialization risks and builds long-term corporate valuation.

Image for illustrative purposes only. Not a real photo.

Compass Pathways reports durable depression trial data

Written by Brie CarterPublished Jul 7, 2026, 10:43 AM

Compass Pathways (NASDAQ:CMPS) announced positive 26-week data from its Phase 3 COMP006 clinical trial evaluating its proprietary synthetic psilocybin formulation, COMP360.
The findings show that nearly 40% of chronic treatment-resistant depression patients maintained a clinically meaningful response six months after receiving two fixed doses.
The company is currently advancing a rolling regulatory submission with the FDA and remains on track to finalize the marketing application by late 2026.

Compass Pathways (NASDAQ:CMPS) announced Phase 3 clinical trial results demonstrating that its proprietary synthetic psilocybin compound, COMP360, provides durable therapeutic relief for treatment-resistant depression.

The clinical program evaluated nearly 600 individuals suffering from chronic depressive episodes that lasted on average for more than three years.

"COMP360 has demonstrated rapid, durable and reproducible clinical effects through at least six months — with a consistent safety profile — across two large, well-controlled Phase 3 studies," said Compass Pathways Chief Medical Officer Doctor Guy Goodwin.

The updated findings revealed that 39% of participants in the 25 mg cohort achieved a significant, long-lasting reduction in baseline depression severity scales through week 26.

The London-based biotechnology corporation specializes in developing evidence-based psychedelic medicine platforms to transform standard mental health care models for underserved populations.

The drug developer expects to complete its final New Drug Application submission during the fourth quarter of 2026 to prepare for an anticipated commercial launch in early 2027.

Compass Pathways reports durable depression trial data

Perguntas frequentes

Ativos relacionados a notícia